The Australian Academy of Health and Medical Sciences elects the best and brightest minds in the field of medical and health sciences as Fellows.

Fellows are elected in recognition of their outstanding achievements and exceptional contributions to the sector. The Fellowship are acknowledged for their clinical, non-clinical, leadership, industry and research contributions.

About Fellowship with AAHMS

Find Fellows of the AAHMS

To find Fellows of our Academy either use the search form below or download the full list of current Fellows here.






Scientia Professor and Head of School, UNSW Psychiatry
University of New South Wales

Philip Mitchell is an international authority in the fields of bipolar disorder and depression, with his major achievements spanning the breadth of genetics, phenomenology, treatment and epidemiology of these conditions. He has identified distinguishing clinical characteristics of bipolar depression, demonstrated specific differences in brain functioning of young people at risk to bipolar disorder, and has published the only two Australian national epidemiological reports on bipolar disorder.

As President of the Australasian Society for Bipolar and Depressive Disorders and Vice-President of the International Society for Bipolar Disorders, Mitchell is a leading discipline figure and a most worthy addition to the Fellowship.







Professor of Clinical Neurosciences; Chair in Physiotherapy
University of South Australia

Professor Moseley has made seminal contributions to our understanding of persistent pain disorders and the role of brain processes in etiology and in treatment. He pioneered intensive pain biology education (‘Explaining pain’) as a treatment for chronic pain, which generated a new field of research and clinical practice. He also developed a specific treatment, which targets disrupted brain processes in chronic pain, that is now recommended in clinical guidelines internationally and considered best practice. His discoveries of cognitive influences over bodily effects have generated new lines of research. His contributions have been recognised by awards and honours on every continent.

Professor of Medicine, Sydney Medical School at Concord Campus
The University of Sydney

Professor Markus Seibel has been an international leader in musculoskeletal medicine for over 25 years. Covering basic, translational and clinical research, Markus has made seminal contributions to the area of skeletal physiology and pathophysiology as well as clinical management of osteoporosis. He has published over 400 scientific articles and edited six academic books. His work has been highly influential being cited >12,000 times. He is Immediate Past-President of the Australian and New Zealand Bone & Mineral Society, Chair of the National Fracture Prevention Alliance and is a Director of the International Federation of Musculoskeletal Research Societies.

Medical Oncologist; Group Leader, Head Parkville Cancer Clinical Trials Unit Breast Oncology
Peter MacCallum Cancer Centre

Professor Sherene Loi has made significant contributions in breast cancer research. These include 1. understanding the role of the immune system and its reaction to breast cancers, 2. how doctors can therapeutically and potentially favourably alter the immune response, 3. development of important new drugs for breast cancer patients including palbocicilb and pertuzumab which have both improved outcomes for breast cancer patients and 4. incorporation of genomic sequencing into clinical care of advanced breast cancer patients to help guide therapy choices. She is an international leader in breast cancer translational research, is widely cited and has over 110 peer-reviewed publications.






ARC Australian Laureate Fellow and Laboratory Head
Monash University

Rossjohn has provided profound insight into T-cell biology, defining the basis of key immune recognition events by T-cells. He has used structural biology to explain pre-T-cell receptor (TCR) self-association in T-cell development, and how the TCR recognises polymorphic Human Leukocyte Antigen (HLA) molecules. He has unearthed mechanisms of HLA polymorphism impacting on drug and food hypersensitivities, as well as Natural Killer cell receptor recognition. He has pioneered our understanding of lipid-based immunity by NKT-cells, and has demonstrated how vitamin B metabolites are recognized by Mucosal-associated invariant T-cells, thereby defining a completely novel class of antigens recognized by T-cells.




Consultant Haematologist and Group Leader
Peter MacCallum Cancer Centre

As a clinician-scientist, Professor Dawson has consistently demonstrated academic excellence and leadership both in basic science discoveries and the translation of these findings into the clinical arena. His research into chromatin regulation of normal and malignant haematopoiesis have provided a range of groundbreaking discoveries including the development in collaboration with GSK of the first clinical therapies that target epigenetic reader proteins. This body of work helped establish a new therapeutic paradigm for the treatment of aggressive malignancies. Importantly, he continues to translate these discoveries by leading the multinational clinical trials that have been initiated as a direct consequence of his research.



Foundation Director
Australian Institute of Health Innovation, Macquarie University

Professor Jeffrey Braithwaite, Foundation Director of the Australian Institute of Health Innovation, and Professor of Health Systems Research, Faculty of Medicine and Health Sciences, Macquarie University researches the way care is delivered to patients and how it can be improved. He has contributed over 700 total publications and presented at international and national conferences on more than 800 occasions, including 80 keynote addresses. His research appears in journals such as British Medical Journal, The Lancet, Social Science & Medicine, and BMJ Quality and Safety. He has received numerous national and international awards for his teaching and research.

Program Head and NHMRC Senior Research Fellow
Kirby Institute, University of New South Wales

Professor Maher is a renowned public health scientist who applies both epidemiological and anthropological approaches to important public health problems – in particular hepatitis C virus (HCV) infection –  including leading the first ever HCV vaccine preparedness study. Her high standing is evidenced by extensive conference invitations as well as an outstanding record of competitive grant funding. This is matched by the respect she enjoys in the wider community, as evidenced by invitations to join high level policy and advisory committees, including the WHO Strategic and Technical Advisory Committee on Viral Hepatitis. She would be a most influential addition to the Fellowship.






Kirby Institute, University of New South Wales

Professor Andrew Lloyd AM is a distinguished infectious diseases physician scientist. He has made major contributions to clinical practice in hepatitis C infection (particularly amongst the prisoner population) and also in chronic fatigue states associated with infection and cancer. He has also made major contributions in laboratory-based studies of the pathophysiology of hepatitis C infection, the acute sickness response to infection and post-infective fatigue states. These studies have led the research direction internationally as well as delivered important clinical practice innovations in Australia. Professor Lloyd has also contributed extensively in research leadership, particularly in the field of viral hepatitis.





Co-Medical Director; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital
Melanoma Institute Australia

Professor Scolyer leads one of world’s largest histopathology consultation practices and is widely regarded as the Australasian point of reference for diagnosis of difficult pigmented skin lesions. He co-leads an award winning translational research program investigating causes, prognostic /predictive biomarkers and treatment of melanoma. He has authored >450 peer-reviewed journal publications (>14,000 citations), and according to Thomson ISI, is the highest ever published scientist worldwide in the field of melanoma pathology and also has highest H index in this field. Professor Scolyer was independently ranked world’s leading melanoma pathologist on multiple occasions. He holds leadership roles in the WHO and AJCC.


Our Fellows sit at the heart of everything we do. They represent Australia’s leading minds in health and medical sciences, having been recognised for their clinical, non-clinical, leadership, industry and research contributions.

To be considered for election to the Academy’s Fellowship, a candidate must show exceptional professional achievement in a field related to health and/or medicine.

Fellows contribute to the projects and activities of the Academy and must be willing to be active participants.

Successful Fellowship candidates will have shown:

  • Outstanding leadership in their field.
  • Significant and ongoing involvement with issues of health care, prevention of disease, education, research, and health services policy and delivery.

Candidates for Fellowship should meet the following criteria:

  • National and International recognition for excellence in health and medical science
  • Significant, sustained and ongoing contributions to advance health and medical science in Australia (relative to opportunity)
  • Contribution to the profession through leadership and mentorship
  • Raised public understanding and promoting health and medical science in the broader community

Download criteria for Fellowship

Each year, current Fellows of the Academy are invited to nominate up to four new candidates who meet the criteria and fulfil the required expectations.

Nominations by a Fellow of two new candidates must ensure that at least one nomination is a woman. Nominations by a Fellow of four new candidates must ensure that at least two nominations are women.

How to make a nomination

Fellows wishing to nominate a candidate for Fellowship should contact the secretariat to confirm candidate eligibility and receive and instructions on how to submit the completed nomination documentation online. 

Fellows wishing to nominate a candidate for a Corresponding Fellowship should contact the secretariat for more information.

Secretariat contact details
Email: [email protected]

Phone: 07 3102 7220

Nomination guidelines for ordinary Fellowship

October 2023
Newly elected Fellows of 2023 are inducted at the Annual Meeting.

18 September 2023- 30 November 2023
Nominations are invited from existing Fellows until the closing date of 30 November.

December 2023
Nominations allocated to Selection Committees.

January – April 2024
Referees’ reports sought.

Early May 2024
Selection Committees meet to consider nominations and provide final recommendations to the Council.

Early-to-mid-July 2024
Council meets to finalise recommendations.

Late July 2024
Full Fellowship invited to comment on recommended new fellows.

August 2024
Election results are shared with proposers and candidates (under embargo).

October 2024
Newly elected Fellows of 2024 inducted at the Annual Meeting.

Keep up to date with the latest news

By providing your email address, you consent to it being added to our mailing list.